NNNN Anbio: שווי פעילות לרווח לפני ריבית, מסים ופחת

Anbio Biotechnology ensures reliability by developing compact AI analyzers for rapid diagnostics. The company's EV/EBITDA ratio over the time series confirms this stability, with 87.62 representing the metric's current value. The robotization of biomaterial screening accelerates development, although fierce competition with healthcare behemoths over test accuracy remains a key external challenge for the business.

To identify fundamental benchmarks in the financial statements of Anbio Biotechnology (NNNN), it is critical to analyze the ratio of total enterprise value, including debt, to its operating profit before depreciation and amortization. By examining the history of the company's EV/EBITDA values, an investor determines capital efficiency, which for a diagnostic equipment manufacturer—given low geopolitical risks and stable global supplies—serves as an indicator of resilience to debt load.